 for one year. She acquisitions articles, writes and edits features, including cover profiles, and handles various special projects. Before joining Advanstar, L.J. was a freelance writer and, in addition to numerous magazine articles, has penned four novels and five scripts. Her most recent novel, 

, will be available from online bookstores in January 2002.

L.J. Sellers

Articles

Lifecycle management and line extensions helped the Percocet franchise generate steady annual growth, rising from $40 million in 1997 sales to $214 million in 2003, despite the fact that it had no patent protection.

Feeling No Pain

Synta is in a very unusual position: Two Big Pharmas have paved the way with proteins, while the small biotech follows with a pill.

Synta's Surprise

We had a vision that this project deserved a company with a focus on HDL as the next frontier in the cardiovascular area.

Cholesterol Champions

Nektar?the drug delivery firm formerly know as Inhale?has been around for 14 years, but its pace during the last few has been dizzying. In 2001, the company made two major acquisitions that not only expanded its technology base from inhaled therapeutics to a broad range of exciting new technologies, but also gave it revenue from five products on the US market that use its technology and lined-up another four in Phase III. In 2002, Nektar brokered 11 collaborative partnerships, and in 2003, it generated $106 million in sales.

Author | L.J. Sellers